A retrospective review from a Miami emergency department assessed whether implementing an evidence-based migraine treatment algorithm could improve adherence to guideline-based care and reduce unnecessary...
Researchers conducted a phase 2/3 randomized clinical trial to better understand the effects of a calcitonin gene-related peptide receptor antagonist for the prevention of migraine.
Migraine is highly prevalent among women of reproductive age, yet data on real-world medication use around conception remain limited. A new Danish study describes patterns of antimigraine medication use...
A post-hoc analysis of the phase 3 REGAIN trial evaluated whether preventive treatment with galcanezumab could shift patients with chronic migraine to episodic migraine frequency, a clinically meaningful...
A recent study found that rimegepant, an orally administered calcitonin gene-related peptide receptor antagonist, is safe and well-tolerated for up to 52 weeks in individuals with migraine, with no signs of...
